Korea/Asia, Events, IPOs, Douglas Research Advisory

Douglas Kim

Nearly 30 years of experience in the Korean/Asian equity research. Major sectors coverage include the following:
- Technology 
- Consumer 
- Special Situations/Deep Value Plays
- Tender Offers/M&As
- Holdcos/Stubs
- Asian Unicorns/Private Companies

Korea/Asia, Events, IPOs

Celltrion (068270 KS): Humira Biosimilar Launch in US; Filed New Biosimilar Marketing Application

Alpha Generation Through Share Buybacks in Korea: June & July 2023

China to Finally Allow Group Tours to Korea and Japan?

Celltrion Group Companies - Sharp Increase in Dividends

Celltrion Inc (068270 KS): Turning Bullish As Biosimilar Revenue Rebounds & US Launches Imminent

Celltrion Merger Announcement in July: Trading Angles Utilizing Appraisal Rights Exercise Dynamics

Celltrion (068270 KS): Disappointing 4Q22 Result; No Immediate Respite Is Seen

Event-Driven

<ul>
<li>Invest Chosun recently reported that the three Celltrion Group companies including Celltrion Inc, Celltrion Healthcare, and Celltrion Pharm are close to announcing a merger in July.</li>
<li>Although Celltrion was not included this time as suppliers of Humira biosimilar products by OptumRX, there is still a potential for Cigna Express Scripts to include Celltrion's product this year.</li>
<li>We think Celltrion Inc and Celltrion Healthcare's share prices are oversold. </li>
</ul>


Invest Chosun recently reported that the three Celltrion Group companies including Celltrion Inc, Celltrion Healthcare, and Celltrion Pharm are close to announcing a merger in July.
Although Celltrion was not included this time as suppliers of Humira biosimilar products by OptumRX, there is still a potential for Cigna Express Scripts to include Celltrion's product this year.
We think Celltrion Inc and Celltrion Healthcare's share prices are oversold. 


Celltrion Group Merger Announcement in July & Oversold Post Disappointing Exclusion by OptumRX?